Categories: DataDrugHealthTechInfrastructureLearnManagementPlatformTechnology
Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created. Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Our discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability. With a lead program candidate expected in the near term, our proprietary pipeline validates our platform with initial programs focused on high-value GPCR targets. We’re pleased to be backed by a strong network of investors including RA Capital Management, Insight Partners, NVIDIA and Gaingels.
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.09.2024 | Series A | $120M | - |
Mentions in press and media 4
| Date | Title | Description |
| 09.09.2024 | Lilly-backed Superluminal raises $120M series A to bring membrane receptor drugs into the clinic | Just over a year after launching with $33 million in seed funding, Boston-based Superluminal Medicines is supercharging its small-molecule drug development with a $120 million series A round backed by the likes of Eli Lilly.
Superluminal fo... |
| 09.09.2024 | Superluminal Medicines Closes $120M Series A Funding | Superluminal Medicines, a Boston, MA-based company that uses generative biology, chemistry and machine learning approaches to create medicines, raised $120M in Series A funding.
The round was led by RA Capital Management with participation ... |
| 04.09.2023 | Superluminal Medicines Raises $33M in Seed Funding | Superluminal Medicines, a Boston, MA-based generative biology and chemistry company, raised $33M in Seed funding.
The round was led by RA Capital Management with participation from Insight Partners, NVIDIA, and Gaingels.
The company intends... |
| - | Superluminal Medicines | “Superluminal Medicines” |
Reviews 0
